



Professor Peter Horby, Professor Martin Landray
RECOVERY trial Co-chairs
Nuffield Department of Population Health
Oxford

21st January 2021

Dear Peter and Martin

RECOVERY trial DMC report

The RECOVERY trial DMC reviewed the safety and efficacy data that were available today for the 29,385 patients randomised. For the interventions still in active recruitment, the numbers included in the comparison of each agent with its control were respectively: tocilizumab (3,721), REGN-COV2 (4,428), aspirin (8,284) and colchicine (5,526).

For all the treatments under study in RECOVERY, in the light of the available trial data and all relevant external information (including the recent pre-print publication of the REMAP-CAP results for Tocilizumab and Sarilumab), we see no cogent reason to modify the protocol or intake to the study.

The DMC will next review the safety and efficacy data for all treatments on 4th February 2021.

Yours sincerely



Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO
Chairman RECOVERY trial DMC
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
t: +44 (0)131 465 9602 / w: www.ccbs.ed.ac.uk / e: Peter.sandercock@ed.ac.uk